Analysis of the gut microbiota in the old order Amish and its relation to the metabolic syndrome.

Autor: Margaret L Zupancic, Brandi L Cantarel, Zhenqiu Liu, Elliott F Drabek, Kathleen A Ryan, Shana Cirimotich, Cheron Jones, Rob Knight, William A Walters, Daniel Knights, Emmanuel F Mongodin, Richard B Horenstein, Braxton D Mitchell, Nanette Steinle, Soren Snitker, Alan R Shuldiner, Claire M Fraser

Publikováno v: PLoS ONE, Vol 7, Iss 8, p e43052 (2012)

Obesity has been linked to the human gut microbiota; however, the contribution of gut bacterial species to the obese phenotype remains controversial because of conflicting results from studies in different populations. To explore the possible dysbios

Externí odkaz: https://doaj.org/article/3b82d425aad046e0955981e35c11d723

Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications.

Autor: Rong-Ze Yang, Mi-Jeong Lee, Hong Hu, Toni I Pollin, Alice S Ryan, Barbara J Nicklas, Soren Snitker, Richard B Horenstein, Kristen Hull, Nelson H Goldberg, Andrew P Goldberg, Alan R Shuldiner, Susan K Fried, Da-Wei Gong

Publikováno v: PLoS Medicine, Vol 3, Iss 6, p e287 (2006)

BackgroundObesity is associated with low-grade chronic inflammation, and serum markers of inflammation are independent risk factors for cardiovascular disease (CVD). However, the molecular and cellular mechanisms that link obesity to chronic inflamma

Externí odkaz: https://doaj.org/article/ba71d96d31e242d392e2e6f9d7f7b178

Prospective Evaluation of Genetic Variation in Platelet Endothelial Aggregation Receptor 1 Reveals Aspirin-Dependent Effects on Platelet Aggregation Pathways

Autor: M Drolet, S Shaub, Braxton D. Mitchell, Joshua D. Backman, Richard B. Horenstein, Laura M. Yerges-Armstrong, Joshua P. Lewis, Jeffery R. O'Connell, Patrick Donnelly, Mary Pavlovich, M Morrisey, Sylvia Newcomer, Keith Tanner

Publikováno v: Clinical and Translational Science. 10:102-109

Genetic variation in the platelet endothelial aggregation receptor 1 (PEAR1) gene, most notably rs12041331, is implicated in altered on-aspirin platelet aggregation and increased cardiovascular event risk. We prospectively tested the effects of aspir

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::064c6de37fe034a206aba626e080a3ca
https://doi.org/10.1111/cts.12438

Multi-site Investigation of Outcomes with Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy after Percutaneous Coronary Intervention

Autor: Issam Hamadeh, Devon C. Nwaba, Nita A. Limdi, Amer Ardati, Josh F. Peterson, James M. Stevenson, Russell A. Wilke, Craig R. Lee, Kristin Weitzel, Tameka D. Alestock, Yan Gong, Kathleen Palmer, Joshua C. Denny, Stephen E. Kimmel, Almut G. Winterstein, Richard B. Horenstein, Mark R. Vesely, Todd C. Skaar, Caitrin W. McDonough, Supatat Chumnumwat, Dyson T. Wake, James H. Willig, Petr Starostik, Larisa H. Cavallari, Linda J. B. Jeng, Karen E. Weck, Chrisly Dillon, Michael J. Clare-Salzler, D. Max Smith, Jorge A. Alsip, Vindhya B. Sriramoju, Rolf P. Kreutz, Chintan V. Dave, Julie A. Johnson, William B. Hillegass, Victoria M. Pratt, Toni I. Pollin, R. David Anderson, Rhonda M. Cooper-DeHoff, Richard Y. Zhao, Yee Ming Lee, Shawn W. Robinson, Brigitta C. Brott, Deepak Voora, Tomasz Stys, Lindsay J. Hines, Alan R. Shuldiner, Ruth E. Pakyz, Mark D. Kelemen, Alison H. Quinn, Edith A. Nutescu, Shuko Harada, Lawrence Brown, David R. Nelson, Oyunbileg Magvanjav, Philip E. Empey, Lucius A. Howell, Amanda R. Elsey, May E. Montasser, Nicholas Varunok, James C. Coons, Amber L. Beitelshees, George A. Stouffer, Julio D. Duarte, Jamie Schub

Objectives This multicenter pragmatic investigation assessed outcomes following clinical implementation of CYP2C19 genotype–guided antiplatelet therapy after percutaneous coronary intervention (PCI). Background CYP2C19 loss-of-function alleles impa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0020458ef2172864006eb4e8685cb22c
https://europepmc.org/articles/PMC5775044/

Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC)

Autor: Dan M. Roden, Marylyn D. Ritchie, Jae-Gook Shin, Braxton D. Mitchell, Teri E. Klein, Gian Franco Gensini, Jurriën M. ten Berg, Pierre Fontana, Lene Holmvang, Israel Fernandez-Cadenas, Willibald Hochholzer, Stefan Winter, Tabassome Simon, Ruth E. Pakyz, Paul A. Gurbel, Richard B. Horenstein, Ming-Shien Wen, Tobias Geisler, John H. Cleator, Marco Valgimigli, Ho-Sook Kim, Jean-Sébastien Hulot, Jolanta M. Siller-Matula, Dietmar Trenk, Gianluca Campo, Michiaki Kubo, Elke Schaeffeler, Nadia Paarup Dridi, Ming Ta Michael Lee, Li Gong, Joshua P. Lewis, Jean-Pierre Déry, Rossella Marcucci, Kiyuk Chang, Meinrad Gawaz, Kevin P. Bliden, Alan R. Shuldiner, Daniel Aradi, Thomas O. Bergmeijer, Betti Giusti, Russ B. Altman, Dimitrios Alexopoulos, Matthias Schwab, Ryan Whaley, Jean-Luc Reny, Joan Montaner, Eun Young Kim

Publikováno v: American Heart Journal
American Heart Journal, Vol. 198 (2018) pp. 152-159
American Heart Journal, Elsevier, 2018, 198, pp.152-159. ⟨10.1016/j.ahj.2017.12.010⟩

RATIONALE: The P2Y(12) receptor inhibitor clopidogrel is widely used in patients with acute coronary syndrome, percutaneous coronary intervention or ischemic stroke. Platelet inhibition by clopidogrel shows wide inter-patient variability and high on-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f3d513bc2b922f707381d003c3eea76
https://pubmed.ncbi.nlm.nih.gov/29653637